Andere Sprachen Werewolf Therapeutics, Inc.

Aktien

A3CM1G

US95075A1079

HOWL

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 23.05.2024			% 5 Tage	% 1. Jan.
5,16 ^USD	+5,52 %		+5,74 %	+33,68 %

23.05.	Werewolf Therapeutics präsentiert aktualisierte Daten der klinischen Phase 1/1b-Studie mit WTX-124 als Monotherapie und in Kombination mit Pembrolizumab bei soliden Tumoren auf der ASCO-Jahrestagung 2024	CI
03.05.	Werewolf Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting	23.05.
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting	23.05.
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	03.05.
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03.05.
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24.04.
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting	23.04.
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	23.04.
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting	05.04.
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	05.04.
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting	04.04.
Werewolf Therapeutics' Q4 Net Loss Narrows	07.03.
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07.03.
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference	06.03.
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024	05.03.
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook	08.01.
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors	04.01.
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	04.01.
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference	22.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Werewolf Therapeutics, Inc.

Aktien

A3CM1G

US95075A1079

HOWL

Andere Sprachen

Filter